Skip to Content

BioScrip brings in turnaround team as losses mount

BioScrip brings in turnaround team as losses mount

ELMSFORD, N.Y. - BioScrip has tapped several new execs and beefed up its board of directors as it repositions itself as a pure play home infusion provider.

“(BioScrip) is a company with significant potential and a strong core business but needs rapid and effective changes to its cost structure,” said Carter Pate, director, during an Aug. 10 earnings call. “We've identified and engaged a leadership that we are confident will be able to implement the board's plan.”

Since March, four new members have been appointed to the board of directors, for a total of seven. Other top-level changes include the appointment of Chris Luthin as COO in August; Britt Jeffcoat as controller and chief accounting officer in May; and Jeffrey Kreger as CFO in April.

BioScrip has also formed a financial improvement committee that will be chaired by Pate.

BioScrip reported second quarter revenues of $247 million for its infusion services segment, an increase of 7.1% compared to the same period in 2014. Overall revenues for the quarter were $262.4 million.

Net losses were $243.2 million for the quarter, compared to $18.6 million one year ago.

As part of its turnaround plans, BioScrip is exploring the sale of non-core assets, like the August sale of Pro Care Pharmacy Benefit Manager for $25 million in cash.

“We believe that sale is a positive outcome,” said Rick Smith, president and CEO. “We are pursuing the sale of other non-core business lines that have created a distraction to the original strategic plan.”

Other cost-cutting measures: reducing the workforce by 12% for a savings of $19 million; and consolidating corporate operations into its Eden Prairie, Minn., location.

“We expect to be a smaller, more focused organization with significantly improved profitability and better prospect for growth,” said Smith.


To comment on this post, please log in to your account or set up an account now.